Zymeworks’s Promising Pipeline and Strategic Partnerships Drive Buy Rating

In a report released on May 9, Andrew Berens from Leerink Partners maintained a Buy rating on Zymeworks (ZYME – Research Report), with a price target of $30.00.

Andrew Berens’s rating is based on Zymeworks’s promising pipeline developments and strategic partnerships. The company’s upcoming pivotal readout for zanidatamab in HER2+ gastric cancer, expected in the second half of 2025, is a significant catalyst. This program, in collaboration with Jazz Pharmaceuticals, holds the potential for a blockbuster opportunity, which could substantially enhance Zymeworks’s market position.
Additionally, Zymeworks is making steady progress with its internal pipeline, with several investigational new drug (IND) submissions planned over the next few years. The recent presentations of preclinical data at the AACR and upcoming trial-in-progress posters at ASCO 2025 further demonstrate the company’s commitment to advancing its diverse portfolio. These factors collectively contribute to Berens’s optimistic outlook and Buy rating for Zymeworks’s stock.

In another report released on May 9, Stifel Nicolaus also maintained a Buy rating on the stock with a $28.00 price target.